Merz Pharma GmbH & Co. KGaA
Merz Pharma GmbH & Co. KGaA, commonly referred to as Merz, is a leading global healthcare company headquartered in Frankfurt, Germany. Founded in 1908, Merz has established a strong presence in the pharmaceutical and medical aesthetics industries, focusing on innovative solutions for neurological disorders, dermatology, and aesthetic medicine. With a commitment to research and development, Merz offers a diverse portfolio of products, including the renowned Xeomin® for neuromodulation and Belotero® for dermal fillers. These offerings are distinguished by their unique formulations and efficacy, catering to both healthcare professionals and patients. Merz has achieved significant milestones, including expansion into key international markets, solidifying its position as a trusted name in the healthcare sector. The company continues to drive advancements in patient care, making it a notable player in the global pharmaceutical landscape.
DitchCarbon Score
How does Merz Pharma GmbH & Co. KGaA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Merz Pharma GmbH & Co. KGaA's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Merz Pharma GmbH & Co. KGaA's reported carbon emissions
Merz Pharma GmbH & Co. KGaA, headquartered in Germany, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is identified as a current subsidiary and inherits its climate commitments and data from its parent organization, Merz Pharma GmbH & Co. KGaA, at a cascade level of 2. Despite the lack of specific emissions data, there are no documented reduction targets or climate pledges available for Merz Pharma. This suggests that the company may still be in the early stages of formalising its climate strategy or reporting practices. In the context of the pharmaceutical industry, companies are increasingly expected to adopt robust climate commitments and transparent reporting on emissions. As Merz Pharma continues to develop its sustainability initiatives, it may align with industry standards and frameworks such as the Science Based Targets initiative (SBTi) in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Merz Pharma GmbH & Co. KGaA is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
